Onsdag 28 Oktober | 18:58:31 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

Alzecure Q1 Update - Inflection point ahead

2023-05-05 11:55:00

Redeye returns with an update following the Q1 report. We continue to believe that the current valuation of the company is undemanding and that important inflection points are ahead, most notably the phase II readout in pain with ACD440 this summer.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/